76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Schrodinger Inc
Closed
SectorHealthcare
20.51 -0.1
Overview
Share price change
24h
Min
19.94
Max
20.71
Income | -20M -60M |
|---|---|
Sales | -29M 60M |
EPS | -0.64 |
Profit margin | -100.432 |
Employees | 891 |
EBITDA | -32M -51M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +55.06% upside |
Next Earnings | 30 Jul 2025 |
|---|
Market Cap | -280M 1.5B |
|---|---|
Previous open | 20.61 |
Previous close | 20.51 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Schrodinger Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Schrodinger Inc Forecast
Price Target
By TipRanks
55.06% upside
12 Months Forecast
Average 31.88 USD 55.06%
High 39 USD
Low 26 USD
Based on 9 Wall Street analysts offering 12 month price targets forSchrodinger Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
